Called the ThunderBolt platform, the inaugural product is an EIA processor, with a completely open software design capable of programming virtually any EIA test.

These tests are widely used to detect and quantify substances such as peptides, proteins, antibodies, and hormones, and to diagnose diseases and conditions including infections, cancer, metabolic disorders, allergies, and autoimmune diseases.

In a single, easily configured run, the flexible ThunderBolt EIA processor can process multiple microtiter plates, while also running up to eight different simultaneous assays. With an onboard reader, the fully automated processor offers a true walkaway solution for labs of any size.

The compact design takes up less than half the workspace of similar EIA automated processors on the market. Cost-effective operation makes the platform suitable for larger clinical laboratories, while it also provides the customizable capabilities needed in hospital or research laboratories.

Gold Standard Diagnostics, Corp. (Davis, CA, USA), a provider of laboratory diagnostics solutions, introduced the ThunderBolt platform at the 2010 Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), which was held at the Anaheim Convention Center (CA, USA) on July 25-29, 2010.

"The ThunderBolt platform represents a true innovation in automated diagnostics instrumentation and is the culmination of nearly 20 years of feedback from laboratory customers around the world,” says John Griffiths, president and CEO of Gold Standard Diagnostics. "By understanding what customers really need, we have been able to build a product that's the right blend of power, flexibility, and ease of use, all at a competitive price.”

GSD provides products, services, and consulting to the diagnostic and medical communities. The company has been creating and cost-effective diagnostics solutions for clinical and hospital laboratories since 2006.

Related Links:
Gold Standard Diagnostics, Corp.
American Association for Clinical Chemistry